Heng‐Huan Lee
- Oncology top 1%
- CAR-T cell therapy research 9
- Viral-associated cancers and disorders 6
- Cancer Immunotherapy and Biomarkers 5
- Cancer Research top 2%
- Immunology top 5%
- Immunotherapy and Immune Responses 7
- Immune Cell Function and Interaction 6
- Molecular Biology top 5%
-
- Lymphoma Diagnosis and Treatment 8
-
- Chronic Lymphocytic Leukemia Research 5
-
- Monoclonal and Polyclonal Antibodies Research 5
- Co-authors
- Mien‐Chie HungJennifer L. HsuWeiya XiaYing‐Nai WangHirohito YamaguchiChia‐Wei LiDihua YuWen-Hsuan Yu
- Cited by
- OncologyCancer ResearchImmunology
- Journals
- Journal of Biological Chemistry (3 papers)Journal of Clinical Investigation (1 paper)Nature Communications (1 paper)
- Partner nations
- United StatesTaiwanChina
In The Last Decade
Heng‐Huan Lee
53 papers receiving 3.4k citations
Hit Papers
Peers
Comparison fields: 5 of 99
- Oncology 1.9k
- Cancer Research 795
- Immunology 831
- Molecular Biology 1.8k
- Pulmonary and Respiratory Medicine 531
Countries citing papers authored by Heng‐Huan Lee
This map shows the geographic impact of Heng‐Huan Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng‐Huan Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng‐Huan Lee more than expected).
Fields of papers citing papers by Heng‐Huan Lee
This network shows the impact of papers produced by Heng‐Huan Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng‐Huan Lee. The network helps show where Heng‐Huan Lee may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Heng‐Huan Lee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 1 | |
| 5 | 2023 | 9 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 5 | |
| 8 | TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosisbreakdown → | 2021 | 255 |
| 9 | 2020 | 133 | |
| 10 | 2019 | 282 | |
| 11 | PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppressionbreakdown → | 2017 | 768 |
| 12 | 2017 | 23 | |
| 13 | 2016 | 203 | |
| 14 | 2014 | 7 | |
| 15 | 2013 | 29 | |
| 16 | 2012 | 62 | |
| 17 | 2011 | 21 | |
| 18 | 2010 | 9 | |
| 19 | 2010 | 98 | |
| 20 | 2010 | 8 |
About Heng‐Huan Lee
Heng‐Huan Lee is a scholar working on Oncology, Immunology and Genetics, having authored 56 papers that have together received 3.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (8 papers), Immunotherapy and Immune Responses (7 papers), Viral-associated cancers and disorders (6 papers), Immune Cell Function and Interaction (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Oncology (1.9k citations), Cancer Research (795 citations) and Immunology (831 citations). Heng‐Huan Lee has collaborated with scholars based in United States, Taiwan and China. Frequent co-authors include Mien‐Chie Hung, Jennifer L. Hsu, Weiya Xia, Ying‐Nai Wang, Hirohito Yamaguchi, Chia‐Wei Li, Dihua Yu, Wen-Hsuan Yu, Gabriel N. Hortobágyi and Jung-Mao Hsu. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.